ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 いまさら聞けない！泌尿器がん化学療法の理論と実践
Ⅲ．がん化学療法の副作用対策
文献概要
要旨 腎・泌尿器系の悪性腫瘍の罹患数は年間約15万人となり，総罹患数としては第1位の大腸がんを上回る。一方，その治療方法は分子標的治療薬のみならず，多種多様な細胞障害性抗がん剤の併用療法が行われており，支持療法の熟知は必須である。そのなかでも，それらの治療方法による骨髄毒性は頻繁に認められるものであり，その支持療法を適切に施行することにより短期的な急性期の毒性の回避のみならず，長期的には抗悪性腫瘍薬の適切な投与量の維持につながり，予後を左右する可能性がある。貧血や血小板減少症においては適切な輸血療法が必要であるが，好中球減少に対しては予防的な持続性G-CSF製剤と抗生物質をガイドラインに基づいて適切に施行すべきである。
参考文献
1）Eisen T, Sternberg CN, Robert C, et al：Targeted therapies for renal cell carcinoma：review of adverse event management strategies. J Natl Cancer Inst 104：93-113, 2012
2）Sternberg CN, Bellmunt J, Sonpavde G, et al：ICUD-EAU International Consultation on Bladder Cancer 2012：Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol 63：58-66, 2013
3）Basch E, Loblaw DA, Oliver TK, et al：Systemic therapy in men with metastatic castration-resistant prostate cancer：American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 32：3436-3448, 2014
4）Beck SD：Optimal management of testicular cancer：from self-examination to treatment of advanced disease. Open Access J Urol 2：143-154, 2010
5）von der Maase H, Hansen SW, Roberts JT, et al：Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer：results of a large, randomized, multinational, multicenter, phase Ⅲ study. J Clin Oncol 18：3068-3077, 2000
6）Sternberg CN, de Mulder PH, Schornagel JH, et al：Randomized phase Ⅲ trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin（MVAC）chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors：European Organization for Research and Treatment of Cancer Protocol no. 30924. Clin Oncol 19：2638-2646, 2001
7）Naito S, Tsukamoto T, Koga H, et al：Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer：a multicenter Phase Ⅱ trial in Japan. Jpn J Clin Oncol 38：365-372, 2008
8）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512, 2004
9）Mukai H, Takahashi S, Nozawa M, et al：Phase Ⅰ dose-escalation and pharmacokinetic study（TED 11576）of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 73：703-710, 2014
10）de Bono JS, Oudard S, Ozguroglu M, et al：Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment：a randomised open-label trial. Lancet 376：1147-1154, 2010
11）Nichols CR, Catalano PJ, Crawford ED, et al：Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors：an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16：1287-1293, 1998
12）Motzer RJ, Hutson TE, Tomczak P, et al：Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356：115-124, 2007
13）Sternberg CN, Davis ID, Mardiak J, et al：Pazopanib in locally advanced or metastatic renal cell carcinoma：results of a randomized phase Ⅲ trial. J Clin Oncol 28：1061-1068, 2010
14）Escudier B, Eisen T, Stadler WM, et al：Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356：125-134, 2007
15）Motzer RJ, Escudier B, Oudard S, et al：Phase 3 trial of everolimus for metastatic renal cell carcinoma：final results and analysis of prognostic factors. Cancer 116：4256-4265, 2010
16）Hudes G, Carducci M, Tomczak P, et al：Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356：2271-2281, 2007
17）Hutson TE, Lesovoy V, Al-Shukri S, et al：Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma：a randomised open-label phase 3 trial. Lancet Oncol 14：1287-1294, 2013
18）Bukowski RM：Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 19：148-154, 2001
19）Escudier B, Eisen T, Stadler WM, et al：Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356：125-134, 2007
20）Motzer RJ, Escudier B, Oudard S, et al：Efficacy of everolimus in advanced renal cell carcinoma：a double-blind, randomised, placebo-controlled phase Ⅲ trial. Lancet 372：449-456, 2008
21）Hudes G, Carducci M, Tomczak P, et al：Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356：2271-2281, 2007
22）Strumberg D：Sorafenib for the treatment of renal cancer. Expert Opin Pharmacother 13：407-419, 2012
23）Demetri GD, van Oosterom AT, Garrett CR, et al：Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib：a randomised controlled trial. Lancet 368：1329-1338, 2006
24）Kent D, Copley M, Benz C, et al：Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin Cancer Res 14：1926-1930, 2008
25）Laplante M and Sabatini DM：mTOR signaling in growth control and disease. Cell 149：274-293, 2012
26）Johnson SC, Rabinovitch PS and Kaeberlein M：mTOR is a key modulator of ageing and age-related disease. Nature 493：338-345, 2013
27）Sabatini DM：mTOR and cancer：insights into a complex relationship. Nat Rev Cancer 6：729-734, 2006
28）Nishiyama N, Takahashi S, Mizuno T, et al：Clinical analysis of febrile neutropenia in urological anticancer chemotherapy：retrospective single center study. Int J Clin Oncol 20：1012-1017, 2015
29）Flowers CR, Seidenfeld J, Bow EJ, et al：Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy：American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31：794-810, 2013
30）Freifeld AG, Bow EJ, Sepkowitz KA, et al：Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer：2010 update by the infectious diseases society of america. Clin Infect Dis 52：e56-93, 2011
31）Crawford J, Caserta C, Roila F, et al：Hematopoietic growth factors：ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21：v248-251, 2010
32）Aapro MS, Bohlius J, Cameron DA, et al：2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47：8-32, 2011
33）Smith TJ, Bohlke K, Lyman GH, et al：Recommendations for the Use of WBC Growth Factors：American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncol 33：3199-3212, 2015
34）Smith TJ, Khatcheressian J, Lyman GH, et al：2006 update of recommendations for the use of white blood cell growth factors：an evidence-based clinical practice guideline. J Clin Oncol 24：3187-3205, 2006
35）Mhaskar R, Clark OA, Lyman G, et al：Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 10：CD003039, 2014
36）Lyman GH, Michels SL, Reynolds MW, et al：Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116：5555-5563, 2010
37）Vehreschild JJ, Bohme A, Cornely OA, et al：Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology（DGHO）. Ann Oncol 25：1709-1718, 2014
38）Fossa SD, Kaye SB, Mead GM, et al：Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16：716-724, 1998
39）Kosaka Y, Rai Y, Masuda N, et al：Phase Ⅲ placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer 23：1137-1143, 2015
40）Hosmer W, Malin J and Wong M：Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 19：333-341, 2011
41）Crawford J and Rodgers GM：Treatment strategies for myeloid growth factors and intravenous iron：when, what, and how? J Natl Compr Canc Netw 12：821-824, 2014
42）Segal BH and Freifeld AG：Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Canc Netw 5：235-242, 2007
43）Gafter-Gvili A, Fraser A, Paul M, et al：Meta-analysis：antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142：979-995, 2005
44）Cullen M, Steven N, Billingham L, et al：Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353：988-998, 2005
45）Rodgers GM 3rd, Becker PS, Blinder M, et al：Cancer— and chemotherapy-induced anemia. J Natl Compr Canc Netw 10：628-653, 2012
46）Rizzo JD, Lichtin AE, Woolf SH, et al：American Society of Clinical Oncology. American Society of Hematology. Use of epoetin in patients with cancer：evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20：4083-4107, 2002
47）Rizzo JD, Brouwers M, Hurley P, et al：American Society of Clinical Oncology, American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28：4996-5010, 2010
48）Brand R, Capadano M and Tempero M：A phase Ⅰ trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15：331-341, 1997
49）von der Maase H, Hansen SW, Roberts JT, et al：Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer：results of a large, randomized, multinational, multicenter, phase Ⅲ study. J Clin Oncol 18：3068-3077, 2000
50）Schiffer CA, Anderson KC, Bennett CL, et al：American Society of Clinical Oncology. Platelet transfusion for patients with cancer：clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19：1519-1538, 2001
掲載誌情報
